A short post explains what people online mean by GLP-1 microdosing, taking doses below the approved levels, and notes none of it is FDA-sanctioned.
Recap by typeshit. Post by Facebook on Facebook.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
A piece on questions about tirzepatide and breast cancer risk. Only the headline is available, so check the source for what the evidence says.
A general rundown of how the two drugs work, who might benefit and what to know before starting, with no new findings or news.
Demócrata reports Lilly's oral GLP-1 met cardiovascular safety and lowered blood sugar and weight in type 2 diabetes. Few details beyond the headline.
Loading…